CN112391341B - Application of SDF-1 protein activator in promoting human umbilical cord mesenchymal stem cell proliferation and differentiation in vitro - Google Patents

Application of SDF-1 protein activator in promoting human umbilical cord mesenchymal stem cell proliferation and differentiation in vitro Download PDF

Info

Publication number
CN112391341B
CN112391341B CN202011370180.4A CN202011370180A CN112391341B CN 112391341 B CN112391341 B CN 112391341B CN 202011370180 A CN202011370180 A CN 202011370180A CN 112391341 B CN112391341 B CN 112391341B
Authority
CN
China
Prior art keywords
sdf
differentiation
mesenchymal stem
umbilical cord
human umbilical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011370180.4A
Other languages
Chinese (zh)
Other versions
CN112391341A (en
Inventor
张川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henan Yuanchuang Life Stem Cell Bank Technology Co ltd
Zhengzhou Bain Biotechnology Co ltd
Zhengzhou Yuanchuang Gene Technology Co ltd
Original Assignee
Henan Yuanchuang Life Stem Cell Bank Technology Co ltd
Zhengzhou Bain Biotechnology Co ltd
Zhengzhou Revo Gene Industry Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henan Yuanchuang Life Stem Cell Bank Technology Co ltd, Zhengzhou Bain Biotechnology Co ltd, Zhengzhou Revo Gene Industry Co ltd filed Critical Henan Yuanchuang Life Stem Cell Bank Technology Co ltd
Priority to CN202011370180.4A priority Critical patent/CN112391341B/en
Publication of CN112391341A publication Critical patent/CN112391341A/en
Application granted granted Critical
Publication of CN112391341B publication Critical patent/CN112391341B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1369—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention discloses an application of an SDF-1 protein activator in promoting in-vitro proliferation and differentiation of human umbilical cord mesenchymal stem cells. The invention discovers that the SDF-1 protein activator has the activity of promoting the proliferation of the hUCMSCs and inducing the osteogenic differentiation of the hUCMSCs, and has concentration effect. Therefore, the SDF-1 protein activator can be used for preparing a culture medium for promoting the proliferation of the hUCMSCs and inducing the osteogenic differentiation of the hUCMSCs. The SDF-1 protein activator is N-trans-p-coumaroyl tyramine.

Description

Application of SDF-1 protein activator in promoting human umbilical cord mesenchymal stem cell proliferation and differentiation in vitro
Technical Field
The invention belongs to the field of stem cells, relates to culture and application of stem cells, and particularly relates to application of an SDF-1 protein activator in promoting in-vitro proliferation and differentiation of human umbilical cord mesenchymal stem cells.
Background
Mesenchymal Stem Cells (MSCs) are a class of adult stem cells derived from early-developmental mesoderm with multipotentiality and self-renewal potential. Sources of MSCs mainly comprise bone marrow, fat, umbilical cord, placenta, amnion and the like. Among them, human umbilical cord mesenchymal stem cells (hUC-MSCs) are the most potential seed cells due to the advantages of convenient material availability, wide source, low immunogenicity and no ethical disputes.
Research shows that the hUC-MSCs have wide clinical application prospect and can be used for treating nervous system diseases, liver and kidney injuries, autoimmune diseases, heart diseases, orthopedic diseases, cardiovascular diseases, diabetes and the like.
The induction of the differentiation of the hUC-MSCs into osteoblasts can be used for treating bone related diseases in bone tissue engineering.
Disclosure of Invention
The invention aims to provide an application of an SDF-1 protein activator for promoting the in-vitro proliferation and differentiation of human umbilical cord mesenchymal stem cells, so as to induce the differentiation of hUC-MSCs into osteoblasts while amplifying the hUC-MSCs.
The technical scheme is as follows:
use of an SDF-1 protein activator for promoting human umbilical cord mesenchymal stem cell proliferation and differentiation in vitro, wherein the differentiation refers to osteogenic differentiation.
Further, the SDF-1 protein activator is N-trans-p-coumaroyl tyramine.
Use of an SDF-1 protein activator for preparing a medium for promoting the in vitro proliferation and differentiation of human umbilical cord mesenchymal stem cells, wherein the differentiation refers to osteogenic differentiation.
Further, the SDF-1 protein activator is N-trans-p-coumaroyl tyramine.
The technical effects are as follows:
the invention discovers that the N-trans-p-coumaroyl tyramine has the activity of promoting the proliferation of hUCMSCs and inducing the osteogenic differentiation of hUCMSCs, and has concentration effect. Therefore, the N-trans-p-coumaroyl tyramine can be used for preparing a culture medium for promoting the proliferation of the hUCMSCs and inducing the osteogenic differentiation of the hUCMSCs.
Drawings
FIG. 1 is an inverted microscope observation result of human umbilical cord mesenchymal stem cells; the visible cells are spindle-shaped and grow in a vortex shape, and the growth characteristics of the human umbilical cord mesenchymal stem cells are met.
FIG. 2 shows the results of alizarin red staining; the results show that the conventional induction group and the dosing induction group generate obvious calcium nodules, and the number of the calcium nodules of the high-concentration dosing induction group is obviously greater than that of the calcium nodules of the low-concentration dosing induction group, so that the obvious osteogenic differentiation is generated.
FIG. 3 shows the Western blot detection results; compared with a normal control group, the SDF-1 protein of the drug-added culture group containing 2 mu M or 5 mu M N-trans-p-coumaroyl tyramine is obviously increased, and the higher the concentration of the N-trans-p-coumaroyl tyramine is, the higher the SDF-1 protein content is. SDF-1 is known to be involved in cell proliferation, and it is presumed that the proliferation promoting effect of N-trans-p-coumaroyl tyramine on hUCMSCs is involved in activation of SDF-1 protein expression.
Detailed Description
First, experimental material
Human umbilical cord mesenchymal stem cells were purchased from Shanghai-passed autumn Biotechnology Ltd.
Fetal bovine serum, DMEM/F12(1:1) medium was purchased from Gibco, USA.
N-trans-p-coumaroyl tyramine is purchased from Dorper method, and the purity is 95-99%.
Second, Experimental methods
1. Culture, passage, morphological observation and phenotype detection of human umbilical cord mesenchymal stem cells
Recovering cryopreserved human umbilical cord mesenchymal stem cells by a conventional method, and culturing in a T25 culture flask with DMEM/F12 culture medium containing 10% fetal calf serum under the conditions of 37 ℃ and 5% CO 2 And saturated humidity. Changing the solution for one time after 2 to 3 days, and carrying out passage when the cells grow to reach 80 to 90 percent of the bottle bottom area. The passage ratio is 1:5, and the method comprises the following steps: placing 0.25% pancreatin-0.53 mM EDTA digestive juice and DPBS at 37 ℃ for preheating, pouring out the culture medium in a culture bottle, adding 3-5mLDPBS into the culture bottle, and removing after light shaking and washing. The pancreatin was diluted 4-fold with DPBS, 2mL of diluted pancreatin was added to the flask, incubated at room temperature for digestion, and after digestion was completed, 2mL of complete medium containing serum was added to stop digestion. Gently blowing the cells on the bottle wall by using a pipette gun to completely shed the cells, then collecting the cell suspension and blowing the cell suspension into single cell suspension, centrifuging at 1200rpm for 5min, removing the supernatant, adding the complete culture medium to suspend the cells, and carrying out passage.
And taking the human umbilical cord mesenchymal stem cells with good growth state after passage for subsequent experiments.
And (3) morphology observation: and (5) observing the form and growth condition of the human umbilical cord mesenchymal stem cells under an inverted microscope, and taking a picture.
And (3) phenotype detection: human umbilical cord mesenchymal stem cells were digested with 0.25% trypsin, resuspended in PBS, and 1X 10 cells were prepared 6 Cell suspension/mL. Then 100 mu L of cell suspension is taken and 20 mu L of labeled primary antibody (CD73-PE, CD90-FITC, CD105-APC, CD34-PE, CD45-APC, HLA-DR-FITC) is incubated for 1h at 4 ℃ in the dark, and the positive rate of the cell phenotype molecules is detected by an upper flow cytometer.
2. Cell proliferation Activity assay
Taking hUCMSCs with good growth state, preparing cell suspension with DMEM/F12 medium containing 10% fetal calf serum, and culturing at a rate of 1 × 10 per well 4 Inoculating each cell in 96-well culture plate, and dividing into normal control group and drug-adding culture group, each group having 5 multiple wells, 37 deg.C, 5% CO 2 After the culture is carried out for 24 hours under the saturated humidity, the drug-adding culture group is replaced by DMEM/F12 culture medium containing 10 percent fetal calf serum and 2 mu M or 5 mu M N-trans-p-coumaroyl tyramine to continue the culture, and the normal control group is replaced by DMEM/F12 culture medium containing 10 percent fetal calf serum to continue the culture. After the culture is continued for 48h, 10 mu L of CCK8 reagent is added into each well, after incubation for 4h, the OD450 value of each well is measured at the wavelength of 450nm of an enzyme-linked immunosorbent assay, the average value of each well is taken, the cell proliferation activity of the drug-added culture group is calculated according to the following formula by taking the cell proliferation activity corresponding to the absorbance value of a normal control group as 100%.
Cell proliferation activity (%) ═ OD dosing culture group/OD normal control group × 100%.
4. Osteogenic differentiation assay
Taking hUCMSCs with good growth state, preparing cell suspension with DMEM/F12 medium containing 10% fetal calf serum, and culturing at a rate of 2 × 10 per well 5 Inoculating each cell in 24-well culture plate, culturing at 37 deg.C with 5% CO 2 And after the culture is carried out for 24 hours under the saturated humidity, continuously culturing according to the following groups, and replacing the corresponding culture medium every 2-3 days.
Normal control group: the culture was continued by changing to DMEM/F12 medium containing 10% fetal bovine serum;
conventional induction group: changing the culture medium into a DMEM/F12 culture medium containing 10 percent fetal calf serum and conventional osteogenic induction factors (100nM dexamethasone, 10mM beta-sodium glycerophosphate and 50mg/L ascorbic acid) to continue culturing;
adding a medicine induction group: the culture was continued by changing to DMEM/F12 medium containing 10% fetal bovine serum, conventional osteogenic inducing factor (100nM dexamethasone +10mM sodium beta-glycerophosphate +50mg/L ascorbic acid) and 2. mu.M or 5. mu. M N-trans-p-coumaroyl tyramide.
And after continuously culturing for 9d, detecting the generation condition of each group of calcium nodules by adopting an alizarin red staining method, and photographing.
5. SDF-1 protein expression assay
Taking hUCMSCs with good growth state, preparing cell suspension with DMEM/F12 medium containing 10% fetal calf serum, and culturing at a rate of 2 × 10 per well 5 Inoculating each cell in 24-well culture plate, and dividing into normal control group and drug-adding culture group, each group having 5 multiple wells, 37 deg.C, 5% CO 2 After the culture for 24h at saturation humidity, the drug-adding culture group is replaced by DMEM/F12 culture medium containing 10% fetal calf serum and 2 mu M or 5 mu M N-trans-p-coumaroyl tyramine for continuous culture, and the normal control group is replaced by DMEM/F12 culture medium containing 10% fetal calf serum for continuous culture. After an additional 48h incubation, cells were collected, washed with PBS, lysed in lysates, and total protein was measured using BCA method. Separating the protein sample by SDS-PAGE gel electrophoresis to obtain the same amount of total protein, transferring to polyvinylidene fluoride membrane, sealing with 5% defatted milk-containing sealing solution, adding anti-SDF-1 and GAPDH primary antibody, shaking overnight at 4 deg.C, adding HRP-labeled secondary antibody, incubating at room temperature for 1h, developing by chemiluminescence method, and collecting the image by gel imager. The bands were scanned and quantified using Image J analysis.
6. Statistical treatment
Data were statistically processed using GraphPad Prism 5.0 software, expressed as x ± s, and comparisons between groups were by t-test, with P < 0.05 indicating significant differences.
Third, experimental results
1. Morphology observation and phenotype detection results of human umbilical cord mesenchymal stem cells
The observation result of the inverted microscope is shown in figure 1, the cells grow in a spindle shape and vortex shape, and the growth characteristics of the human umbilical cord mesenchymal stem cells are met. The results of the phenotypic detection are shown in table 1, the expression levels of CD34, CD45 and HLA-DR are very low, and the expression levels of CD73, CD90 and CD105 are very high, which are in line with the phenotypic characteristics of human umbilical cord mesenchymal stem cells.
TABLE 1 molecular Positive rates for cell phenotypes
Molecular positive rate of cell phenotype Positive rate (%)
CD73 98.5
CD90 98.8
CD105 98.2
CD34 2.73
CD45 1.69
HLA-DR 0.87
2. Cell proliferation Activity assay results
As shown in Table 2, the cell growth activity of each group was higher in the drug-added culture group containing 2. mu.M or 5. mu. M N-trans-p-coumaroyl tyramine than in the normal control group.
TABLE 2 cell proliferation Activity of each group
Cell proliferation Activity
Normal control group (100.00±0.73)％
Medicine culture group (2 μ M) (175.28±1.15)％
Medicine culture group (5 mu M) (283.95±1.42)％
As can be seen from the above table, N-trans-p-coumaroyltyramine has a concentration-dependent effect on the proliferation-promoting activity of hUCMSCs.
3. Results of osteogenic differentiation assay
The results of osteogenic differentiation tests show that the conventional induction group and the drug-adding induction group both generate obvious calcium nodules, and the number of the calcium nodules in the high-concentration drug-adding induction group is obviously greater than that in the low-concentration drug-adding induction group (as shown in figure 2), so that the osteogenic differentiation is obvious. No obvious calcium nodules were detected in the normal control group.
The formation of mineralized nodules is the final stage of osteogenic differentiation and is an important marker of osteogenic differentiation in vitro. The results indicate that N-trans-p-coumaroyl tyramine has the effect of inducing osteogenic differentiation of hUCMSCs, and shows a dose-dependent effect.
4. SDF-1 protein expression test results
As shown in FIG. 3, the results of Western blot analysis show that SDF-1 protein in the drug-added culture group containing 2. mu.M or 5. mu. M N-trans-p-coumaroyl tyramine is significantly increased, and the higher the concentration of N-trans-p-coumaroyl tyramine is, the higher the SDF-1 protein content is. SDF-1 is known to be involved in cell proliferation, and the proliferation promoting effect of N-trans-p-coumaroyl tyramine on hUCMSCs is presumed to be involved in activating SDF-1 protein expression.

Claims (2)

1. The application of an SDF-1 protein activator in promoting the in-vitro proliferation and differentiation of human umbilical cord mesenchymal stem cells, wherein the differentiation refers to osteogenic differentiation, and the SDF-1 protein activator is N-trans-p-coumaroyl tyramine.
2. Use of an SDF-1 protein activator for preparing a culture medium for promoting in vitro proliferation and differentiation of human umbilical cord mesenchymal stem cells, wherein the differentiation refers to osteogenic differentiation, and the SDF-1 protein activator is N-trans-p-coumaroyl tyramine.
CN202011370180.4A 2020-11-30 2020-11-30 Application of SDF-1 protein activator in promoting human umbilical cord mesenchymal stem cell proliferation and differentiation in vitro Active CN112391341B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011370180.4A CN112391341B (en) 2020-11-30 2020-11-30 Application of SDF-1 protein activator in promoting human umbilical cord mesenchymal stem cell proliferation and differentiation in vitro

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011370180.4A CN112391341B (en) 2020-11-30 2020-11-30 Application of SDF-1 protein activator in promoting human umbilical cord mesenchymal stem cell proliferation and differentiation in vitro

Publications (2)

Publication Number Publication Date
CN112391341A CN112391341A (en) 2021-02-23
CN112391341B true CN112391341B (en) 2022-08-19

Family

ID=74605590

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011370180.4A Active CN112391341B (en) 2020-11-30 2020-11-30 Application of SDF-1 protein activator in promoting human umbilical cord mesenchymal stem cell proliferation and differentiation in vitro

Country Status (1)

Country Link
CN (1) CN112391341B (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102732478A (en) * 2012-06-15 2012-10-17 四川大学华西医院 Inducer for inducing directional differentiation of umbilical cord mesenchymal stem cells into bladder smooth muscle cells and preparation and application thereof
CN108355167A (en) * 2018-04-27 2018-08-03 昆明医科大学第附属医院 A kind of chitosan coating BCBB bone renovating bracket materials and preparation method thereof being sustained SDF-1
CN111534483B (en) * 2020-05-23 2020-12-18 广东壹加再生医学研究院有限公司 Application of insulin-like growth factor binding protein 7 activator in chondrogenic differentiation of human umbilical cord mesenchymal stem cells
CN111518760A (en) * 2020-05-24 2020-08-11 南京凡亦达生物科技有限公司 Culture medium for promoting in-vitro proliferation and differentiation of umbilical cord mesenchymal stem cells
CN111690686B (en) * 2020-07-19 2021-01-15 广西康久生物科技有限公司 Application of miRNA high expression in promoting in-vitro proliferation and osteogenic differentiation of umbilical cord mesenchymal stem cells
CN111662868B (en) * 2020-07-20 2021-03-30 北京达尔文细胞生物科技有限公司 CXCR4 agonist and application thereof in-vitro culture of umbilical cord mesenchymal stem cells

Also Published As

Publication number Publication date
CN112391341A (en) 2021-02-23

Similar Documents

Publication Publication Date Title
KR101211913B1 (en) Medium for Culturing Mesenchymal Stem Cells Derived from Amnion and Method for Culturing Mesenchymal Stem Cells Derived from Amnion Using thereof
CN107828722B (en) Stem cell specifically expressing PD-1, and identification and separation method and application thereof
Song et al. Effects of human adipose-derived mesenchymal stem cells combined with estrogen on regulatory T cells in patients with premature ovarian insufficiency
CN107709575B (en) Method for assessing purity of mesenchymal stem cell preparation
Wang et al. The utility of human fallopian tube mucosa as a novel source of multipotent stem cells for the treatment of autologous reproductive tract injury
Pilbauerova et al. Enzymatic Isolation, Amplification and Characterization of Dental Pulp Stem Cells.
KR20210044749A (en) Serum-free medium composition
Shanbhag et al. Xeno-free spheroids of human gingiva-derived progenitor cells for bone tissue engineering
WO2017059566A1 (en) Composition for rapidly separating adipose tissue-derived stromal cells
CN108486039B (en) Method for inducing human adipose-derived stem cells to differentiate into testicular interstitial cells by using small molecules
Harrison et al. Establishing the adipose stem cell identity: Characterization assays and functional properties
CN106834217B (en) Method for promoting in-vitro amplification of human amniotic epithelial cells and application
CN112391341B (en) Application of SDF-1 protein activator in promoting human umbilical cord mesenchymal stem cell proliferation and differentiation in vitro
Kadkhoda et al. Assessment of surface markers derived from human periodontal ligament stem cells: an in vitro study
CN105886462A (en) Composition ADSCs for ADSCs culture and ADSCs culture method
CN1920010A (en) Method of separating multipotent adult progenitor cells from umbilical cord blood
CN112481213B (en) Application of small molecule active peptide in inducing hUC-MSCs differentiation
CN113832108A (en) Umbilical cord mesenchymal stem cell exosome and application thereof in resisting skin aging
CN113913377A (en) Culture medium capable of improving osteogenic differentiation efficiency of human mesenchymal stem cells and culture method
TW202214843A (en) Methods for promoting proliferation and propagation of stem cells
CN111437289A (en) Application of mannose in enhancing immunoregulation capability of mesenchymal stem cells
BOHÁČ et al. Comparative Analysis of Somatic Stem Cells With Emphasis on Osteochondral Tissue Regeneration
CN112481219B (en) Application of high gene expression in promoting proliferation of human umbilical cord mesenchymal stem cells in-vitro culture
US20220106569A1 (en) Methods for promoting proliferation and propagation of stem cells
CN114276987A (en) Method for inhibiting replicative senescence of mesenchymal stem cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220713

Address after: 202155 No. 492 qiaosong Road, Chengqiao Town, Chongming District, Shanghai (Shanghai Chengqiao Economic Development Zone)

Applicant after: Suxuan (Shanghai) Biotechnology Co.,Ltd.

Address before: Jiangning campus of Nanjing Medical University, 101 longmian Avenue, Jiangning District, Nanjing City, Jiangsu Province, 211166

Applicant before: Zhang Chuan

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220802

Address after: 450000 building 11, Zhengzhou airport biomedical park, northeast corner of the intersection of Huanghai Road and biotechnology Second Street, Hangkong port area, Zhengzhou City, Henan Province

Applicant after: ZHENGZHOU REVO GENE INDUSTRY Co.,Ltd.

Applicant after: Zhengzhou Bain Biotechnology Co.,Ltd.

Applicant after: Henan Yuanchuang life stem cell bank technology Co.,Ltd.

Address before: 202155 No. 492 qiaosong Road, Chengqiao Town, Chongming District, Shanghai (Shanghai Chengqiao Economic Development Zone)

Applicant before: Suxuan (Shanghai) Biotechnology Co.,Ltd.

GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 450000 building 11, Zhengzhou airport biomedical park, northeast corner of the intersection of Huanghai Road and biotechnology Second Street, Hangkong port area, Zhengzhou City, Henan Province

Patentee after: Zhengzhou Yuanchuang Gene Technology Co.,Ltd.

Patentee after: Zhengzhou Bain Biotechnology Co.,Ltd.

Patentee after: Henan Yuanchuang life stem cell bank technology Co.,Ltd.

Address before: 450000 building 11, Zhengzhou airport biomedical park, northeast corner of the intersection of Huanghai Road and biotechnology Second Street, Hangkong port area, Zhengzhou City, Henan Province

Patentee before: ZHENGZHOU REVO GENE INDUSTRY Co.,Ltd.

Patentee before: Zhengzhou Bain Biotechnology Co.,Ltd.

Patentee before: Henan Yuanchuang life stem cell bank technology Co.,Ltd.